Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Merck & Co. Inc. pages available for free this week:
- Balance Sheet: Assets
- Cash Flow Statement
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value (EV)
- Dividend Discount Model (DDM)
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Merck & Co. Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
- Debt to equity ratio
- The debt to equity ratio exhibits variability over the observed periods. Starting at 1.07 in March 2020, it peaked at 1.26 in December 2020, indicating an increase in leverage. Subsequently, it declined steadily to 0.66 by December 2022, reflecting a reduction in reliance on debt relative to equity. The ratio then showed a moderate resurgence, reaching 0.95 in June 2023, before gradually decreasing to 0.72 by the end of the forecast period in March 2025. Overall, this suggests a trend towards more conservative financial structure after an initial increase.
- Debt to capital ratio
- This ratio follows a similar pattern to the debt to equity ratio. It rose from 0.52 in March 2020 to a high of 0.56 in December 2020, indicating a larger proportion of debt in the capital structure. Thereafter, it steadily declined to 0.40 by December 2022, pointing to deleveraging. A temporary increase occurred mid-2023, reaching 0.49 in June 2023, followed by a gradual reduction to 0.42 by March 2025. The data implies a strategic reduction in debt financing over time with some short-term fluctuations.
- Debt to assets ratio
- The debt to assets ratio shows less volatility, beginning at 0.33 in March 2020 and peaking at 0.35 in December 2020, consistent with the higher leverage observed in other metrics. Subsequently, it decreases to around 0.28 by December 2022, maintaining relative stability thereafter with slight fluctuations between 0.30 and 0.34. By March 2025, the ratio stands at 0.30, suggesting a stable proportion of assets financed through debt over the period.
- Financial leverage
- Financial leverage experienced an initial increase from 3.24 in March 2020 to 3.62 in December 2020, consistent with heightened debt levels. Following this peak, a notable downward trend occurs, reaching 2.30 by December 2022, indicating reduced use of debt in the capital structure and potentially stronger equity base or asset growth. After a brief rise to 2.84 in December 2023, the ratio trends downward again, ending at 2.38 in March 2025. Overall, the trend reflects a strategy of deleveraging and strengthening financial stability over the long term.
Debt Ratios
Debt to Equity
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Loans payable and current portion of long-term debt | ||||||||||||||||||||||||||||
Long-term debt, excluding current portion | ||||||||||||||||||||||||||||
Total debt | ||||||||||||||||||||||||||||
Total Merck & Co., Inc. stockholders’ equity | ||||||||||||||||||||||||||||
Solvency Ratio | ||||||||||||||||||||||||||||
Debt to equity1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Debt to Equity, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Debt to equity = Total debt ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends related to the company's debt and equity structure over the analyzed periods.
- Total Debt
- The total debt exhibits fluctuations throughout the periods. It initially increased from approximately 28 billion USD in March 2020 to over 33 billion USD by December 2021. Subsequently, it declined to around 30 billion USD by the end of 2022. However, a resurgence occurred, with debt reaching nearly 37 billion USD by June 2024 before declining again to approximately 35 billion USD by March 2025. These variations indicate active management of the company's debt levels, possibly reflecting strategic financing decisions or responses to market conditions.
- Total Stockholders’ Equity
- Stockholders’ equity generally demonstrates an upward trend from about 26 billion USD in March 2020, peaking close to 47 billion USD by March 2025. Despite some volatility—particularly noticeable dips around June 2023 and December 2023—equity gains dominate the overall trend, suggesting sustained growth in the company's net assets over the period.
- Debt to Equity Ratio
- The debt-to-equity ratio shows marked variability, ranging from a high of approximately 1.26 at the end of 2020 to a low near 0.66 by the end of 2022. This ratio initially increased during 2020, indicating rising leverage, but then declined significantly through 2022, reflecting a better equity buffer relative to debt. The ratio increased again during 2023 reaching near 0.95, before trending downward toward 0.72 by March 2025. The oscillations in this ratio mirror the movements in both debt and equity, indicating fluctuating leverage levels with an overall trend towards moderate leverage in recent periods.
Overall, the data suggests the company has managed its capital structure with some variability in leverage but an underlying increase in equity, which could be interpreted as a strengthening financial position. The observed debt fluctuations may be linked to financing strategies or external factors affecting the company’s capital needs.
Debt to Capital
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Loans payable and current portion of long-term debt | ||||||||||||||||||||||||||||
Long-term debt, excluding current portion | ||||||||||||||||||||||||||||
Total debt | ||||||||||||||||||||||||||||
Total Merck & Co., Inc. stockholders’ equity | ||||||||||||||||||||||||||||
Total capital | ||||||||||||||||||||||||||||
Solvency Ratio | ||||||||||||||||||||||||||||
Debt to capital1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Debt to Capital, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable trends regarding the company's debt and capital structure over the observed periods.
- Total Debt
- Total debt exhibited fluctuations throughout the timeline. Starting at approximately $27.998 billion in the first quarter of 2020, the debt level increased to around $31.102 billion at the end of 2021. Following this peak, the debt figure showed a general oscillation between roughly $30 billion and $37 billion. There was a notable increase in mid-2023 reaching around $36.911 billion, followed by subsequent fluctuations but an overall downward movement observed toward the first quarter of 2025 when total debt decreased to approximately $34.844 billion. This pattern suggests active management of debt levels in response to operational or market conditions.
- Total Capital
- Total capital consistently increased over the reporting periods with some minor variations. Beginning near $54.203 billion in early 2020, capital rose steadily, surpassing $72.686 billion by the end of 2021. This upward trend persisted, reaching highs above $83 billion by early 2025. The overall increase in total capital indicates growth in the firm's financial base, potentially through retained earnings, issuance of equity, or other capital inflows.
- Debt to Capital Ratio
- The debt to capital ratio started at 0.52 in March 2020, indicating that slightly more than half of the capital structure was financed through debt at that time. This ratio fluctuated considerably, decreasing to lows around 0.40 in late 2022 and early 2023. The ratio then increased again, approaching approximately 0.49 in mid-2023, before gradually declining back to approximately 0.42 by the first quarter of 2025. These movements reflect the interplay between changes in total debt and total capital. Generally, a decreasing debt-to-capital ratio over time can be interpreted as a reduction in leverage and potentially lower financial risk.
In summary, the company demonstrated a dynamic approach to managing debt and capital, with total capital expanding steadily while debt levels varied but remained within a controlled range. The decline in the debt-to-capital ratio over the longer term suggests improved capital structure balance and possibly an enhanced credit profile.
Debt to Assets
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Loans payable and current portion of long-term debt | ||||||||||||||||||||||||||||
Long-term debt, excluding current portion | ||||||||||||||||||||||||||||
Total debt | ||||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||||
Solvency Ratio | ||||||||||||||||||||||||||||
Debt to assets1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Debt to Assets, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
- Total debt exhibited fluctuations over the observed periods. Initially, there was a gradual increase from approximately 28.0 billion USD in March 2020 to a peak of around 33.1 billion USD by December 2021. Subsequently, total debt experienced minor declines and recoveries, reaching a high point near 38.1 billion USD in mid-2024. After this peak, a downward trend is noted, with total debt decreasing to approximately 34.8 billion USD by March 2025. Overall, the debt level shows cyclical movements with significant peaks and troughs rather than a steady trend.
- Total Assets
- Total assets generally trended upward throughout the period, beginning at roughly 84.9 billion USD in March 2020 and increasing notably to over 117.5 billion USD in June 2024. There is a consistent pattern of asset growth, with some periods of stabilization or slight decline, such as in 2023, but the overall direction remains positive. This growth suggests ongoing investments or asset accumulation over time.
- Debt to Assets Ratio
- The debt to assets ratio fluctuated moderately within a range of approximately 0.28 to 0.35. Initially, the ratio was around 0.33 at the start of 2020, then declined to lows near 0.28 by late 2020 and early 2022. This reduction indicates that debt grew at a slower pace than assets during that timeframe. Later, the ratio increased again, reaching about 0.35 in the first half of 2023, reflecting a period when debt increased more rapidly relative to assets. Toward the end of the observed timeline, the ratio stabilized around 0.30, implying a more balanced relationship between debt and asset growth.
Financial Leverage
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||||
Total Merck & Co., Inc. stockholders’ equity | ||||||||||||||||||||||||||||
Solvency Ratio | ||||||||||||||||||||||||||||
Financial leverage1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Financial Leverage, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Financial leverage = Total assets ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable trends across the key metrics of the company over the examined period.
- Total assets
- The total assets have generally exhibited an upward trajectory from March 2020 to March 2025. Starting at approximately 84.9 billion US dollars in early 2020, the assets increased steadily, with some minor fluctuations, reaching a peak of around 117.5 billion US dollars by mid-2024. Towards the end of the period, a slight decline was observed, with total assets reducing to about 115.1 billion US dollars by March 2025. This overall increase indicates ongoing asset growth and suggests ongoing investment or acquisition activity.
- Total stockholders’ equity
- Stockholders’ equity demonstrated a positive growth trend, rising from about 26.2 billion US dollars at the beginning of 2020 to 48.3 billion US dollars by the end of the observed period in March 2025. The equity increased steadily with occasional periods of relatively slower growth, such as a dip observed between late 2022 and mid-2023. Despite this, the general upward momentum points to retained earnings accumulation and possibly new equity issuance, contributing to enhanced shareholder value.
- Financial leverage
- Financial leverage, which reflects the ratio of total assets to stockholders’ equity, has generally trended downward, moving from a high of approximately 3.6 in late 2020 to around 2.4 by early 2025. The reduction in leverage suggests a gradual strengthening of the equity base relative to assets, indicating reduced reliance on debt financing. There were intermittent increases in leverage, such as the rise in late 2023, but the overall pattern points to a stabilization and moderation in the company’s capital structure risk profile.
In summary, the data indicates a company experiencing steady growth in both assets and equity while prudently managing its financial leverage. The trends imply a cautious approach to debt, favoring an improved equity position, which may enhance financial stability and support future strategic initiatives.